Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

BioWest Therapeutics Inc75 enrolled

Overview

This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Acne Vulgaris Acne Propionibacterium Acnes

Interventions

MBI 226 Acne SolutionsDRUG

Eligibility

Sex: ALLMin age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females, ages 13 and up, exhibiting high levels of facial P. acnes * Presence of inflammatory and non-inflammatory lesions Exclusion Criteria: * Acne conglobata, acne fulminans, or secondary acne (chlorine, drug-induced acne, etc.) * Active facial cysts

Outcomes

Primary Outcomes

- percent change in inflammatory, non-inflammatory, and total acne lesion counts over entire study and dichotomized Global Severity Assessment

Secondary Outcomes

- percent change in lesion counts after ~2 and ~4 weeks

- Global Severity Assessment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.